• Mark Terry
• 19 Apr, 2021

AstraZeneca announced that its Farxiga (dapagliflozin) failed to hit the endpoints in its Phase III DARE-19 study in hospitalized COVID-19 patients at serious risk of developing complications. It also failed to assist hospitalized patients with recovery. The drug is a first-in-class, oral, once-daily SGLT2 inhibitor approved by the FDA to decrease the risk of hospitalization for heart failure in type 2 diabetes and with cardiovascular disease or multiple cardiovascular risk factors.
Read more...